Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

Zenas BioPharma

Contributing Author

Recent Articles by Zenas BioPharma

Sep-22
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026 ZBIO GlobeNewswire
Sep-18
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
Sep-08
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event ZBIO GlobeNewswire
Sep-04
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences ZBIO GlobeNewswire
Aug-18
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
Aug-13
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update ZBIO -6.68% GlobeNewswire
Jul-17
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
Jun-17
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO ZBIO +6.46% GlobeNewswire
Jun-11
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit ZBIO ZBIO +11.49% GlobeNewswire
Jun-02
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine ZBIO -5.72% GlobeNewswire
May-28
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD ZBIO GlobeNewswire
May-19
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress ZBIO +5.50% GlobeNewswire
May-18
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO -7.80% GlobeNewswire
May-13
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor ZBIO GlobeNewswire
May-13
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update ZBIO GlobeNewswire
Apr-17
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
Mar-27
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million ZBIO -17.82% GlobeNewswire
Mar-26
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock ZBIO GlobeNewswire
Mar-16
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
Mar-16
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update ZBIO GlobeNewswire
Feb-20
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
Feb-09
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 ZBIO GlobeNewswire
Feb-04
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 ZBIO GlobeNewswire
Jan-16
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
Jan-05
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) ZBIO -51.86% GlobeNewswire
Dec-19
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZBIO ZBIO +17.10% GlobeNewswire
Dec-15
Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus ZBIO -19.71% GlobeNewswire
Nov-12
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update ZBIO GlobeNewswire
Nov-11
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences ZBIO +8.41% GlobeNewswire
Oct-27
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis ZBIO +33.08% GlobeNewswire
Oct-08
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis ZBIO +24.22% GlobeNewswire
Sep-02
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million ZBIO +9.50% GlobeNewswire
Aug-26
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences ZBIO GlobeNewswire
Aug-12
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates ZBIO +6.68% GlobeNewswire
Jun-20
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ZBIO GlobeNewswire
May-29
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference ZBIO +8.34% GlobeNewswire
May-15
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates ZBIO +12.21% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)